These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

991 related items for PubMed ID: 22534616

  • 1. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H.
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [Abstract] [Full Text] [Related]

  • 2. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee ST, Jang JH, Suh HC, Hahn JS, Ko YW, Min YH.
    Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
    [Abstract] [Full Text] [Related]

  • 3. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
    Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL.
    J Clin Oncol; 2008 Nov 10; 26(32):5192-7. PubMed ID: 18854573
    [Abstract] [Full Text] [Related]

  • 4. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
    Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F.
    Cancer; 2003 Mar 15; 97(6):1481-7. PubMed ID: 12627513
    [Abstract] [Full Text] [Related]

  • 5. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, Dipersio JF, Vij R.
    Am J Hematol; 2009 Nov 15; 84(11):733-7. PubMed ID: 19806665
    [Abstract] [Full Text] [Related]

  • 6. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S, Rahamim E, Sarid N, Rozovski U, Gibstein L, Aviv F, Kirsner I, Naparstek E.
    Clin Lymphoma Myeloma Leuk; 2012 Dec 15; 12(6):438-43. PubMed ID: 23017331
    [Abstract] [Full Text] [Related]

  • 7. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
    de Witte T, Suciu S, Meert L, Halkes C, Selleslag D, Bron D, Amadori S, Willemze R, Muus P, Baron F.
    Ann Hematol; 2015 Dec 15; 94(12):1981-9. PubMed ID: 26410352
    [Abstract] [Full Text] [Related]

  • 8. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Koller CA, Kantarjian HM, Feldman EJ, O'Brien S, Rios MB, Estey E, Keating M.
    Cancer; 1999 Dec 01; 86(11):2246-51. PubMed ID: 10590364
    [Abstract] [Full Text] [Related]

  • 9. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
    Bergua JM, Montesinos P, Martinez-Cuadrón D, Fernández-Abellán P, Serrano J, Sayas MJ, Prieto-Fernandez J, García R, García-Huerta AJ, Barrios M, Benavente C, Pérez-Encinas M, Simiele A, Rodríguez-Macias G, Herrera-Puente P, Rodríguez-Veiga R, Martínez-Sánchez MP, Amador-Barciela ML, Riaza-Grau R, Sanz MA, PETHEMA group.
    Br J Haematol; 2016 Sep 01; 174(5):700-10. PubMed ID: 27118319
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G.
    Leukemia; 2016 Feb 01; 30(2):268-73. PubMed ID: 26365212
    [Abstract] [Full Text] [Related]

  • 11. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, Piccaluga PP, Michelutti A, Simeone E, Damiani D, Russo D, Fanin R.
    Leuk Res; 2008 Dec 01; 32(12):1800-8. PubMed ID: 18621416
    [Abstract] [Full Text] [Related]

  • 12. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
    Brunnberg U, Mohr M, Noppeney R, Dürk HA, Sauerland MC, Müller-Tidow C, Krug U, Koschmieder S, Kessler T, Mesters RM, Schulz C, Kosch M, Büchner T, Ehninger G, Dührsen U, Serve H, Berdel WE.
    Ann Oncol; 2012 Apr 01; 23(4):990-6. PubMed ID: 21810729
    [Abstract] [Full Text] [Related]

  • 13. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV, Konopacki J, Thepenier C, Eddou H, Foissaud V, de Revel T.
    Ann Hematol; 2012 Dec 01; 91(12):1871-7. PubMed ID: 22820971
    [Abstract] [Full Text] [Related]

  • 14. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
    Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H.
    Am J Hematol; 2014 Oct 01; 89(10):964-8. PubMed ID: 24990142
    [Abstract] [Full Text] [Related]

  • 15. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X, Mei C, Zhang J, Lu Y, Lan J, Lin S, Zhang Y, Kuang Y, Ren Y, Ma L, Wei J, Ye L, Xu W, Li K, Lu C, Jin J, Tong H.
    Hematol Oncol; 2020 Oct 01; 38(4):531-540. PubMed ID: 32469434
    [Abstract] [Full Text] [Related]

  • 16. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q.
    Leuk Lymphoma; 2009 Sep 01; 50(9):1461-7. PubMed ID: 19672772
    [Abstract] [Full Text] [Related]

  • 17. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
    Candoni A, Papayannidis C, Martinelli G, Simeone E, Gottardi M, Iacobucci I, Gherlinzoni F, Visani G, Baccarani M, Fanin R.
    Am J Hematol; 2018 May 01; 93(5):655-663. PubMed ID: 29396857
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH.
    J Clin Oncol; 1997 Aug 01; 15(8):2780-5. PubMed ID: 9256119
    [Abstract] [Full Text] [Related]

  • 19. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Aug 01; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 20. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S.
    J Clin Oncol; 1994 Apr 01; 12(4):671-8. PubMed ID: 7512125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.